Sarepta Therapeutics Income Statement (2010-2025) | SRPT

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	146.93M	164.09M	189.41M	201.46M	210.83M	22.25M	22.50M	777.02M	22.00M	22.25M	309.32M	1,078.13M	413.46M	362.93M	467.17M	658.41M	744.86M	611.09M	399.36M	442.93M
Cost of Revenue (Quarter)	22.35M	19.52M	23.44M	31.74M	31.44M	37.80M	39.95M	30.80M	35.02M	34.12M	37.03M	44.18M	50.56M	44.55M	91.69M	132.30M	137.56M	152.56M	150.78M	398.71M
Gross Profit (Quarter)	124.58M	144.57M	165.96M	169.72M	179.39M	-15.54M	-17.46M	746.22M	-13.01M	-11.87M	272.30M	1,033.95M	362.90M	318.39M	375.48M	526.11M	607.29M	458.53M	248.58M	44.23M
Operating items
Amortization - Intangibles (Quarter)	0.17M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.44M	0.76M	0.60M	0.60M	0.60M	0.60M	0.60M	0.67M	0.68M	0.68M
Research & Development (Quarter)	195.15M	239.62M	139.12M	197.30M	194.25M	252.33M	216.71M	213.80M	245.68M	241.89M	194.30M	195.52M	200.40M	179.69M	224.48M	199.95M	773.45M	204.39M	218.89M	325.34M
Selling, General & Administrative (Quarter)	71.13M	72.35M	61.13M	78.06M	71.84M	154.32M	104.79M	120.48M	110.71M	118.56M	120.89M	131.70M	127.00M	138.80M	128.20M	163.87M	133.63M	137.90M	91.89M	128.30M
Restructuring Costs (Quarter)																			40.51M	1.49M
Other Operating Expenses (Quarter)	32.52M	102.00M			31.62M				35.20M	102.00M			51.16M				138.16M	153.22M	151.45M	399.39M
Operating Expenses (Quarter)	298.80M	331.66M	223.86M	307.27M	297.71M	444.62M	361.62M	365.26M	391.59M	394.76M	352.66M	372.16M	378.56M	363.63M	444.98M	496.73M	1,045.24M	495.51M	502.75M	854.52M
Operating Income (Quarter)	-151.87M	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M
EBIT (Quarter)	-151.87M	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M
Non-operating items
Interest & Investment Income (Quarter)	0.06M	0.05M	0.15M	0.10M	0.17M	2.41M	4.78M	9.13M
Other Non Operating Income (Quarter)	0.06M	-0.41M	-0.31M	0.66M			98.50M	5.53M	387.30M				6.54M	14.28M	11.81M	10.06M	-83.13M	38.06M	138.60M	-121.74M
Non Operating Income (Quarter)	-15.53M	-0.41M	-13.45M	-16.08M	-17.27M	-16.96M	0.38M	5.53M	12.71M	16.93M	-12.33M	301.07M	6.54M	14.28M	11.81M	10.06M	-83.13M	38.06M	47.95M	-5.33M
Net income details
EBT (Quarter)	-167.39M	-81.76M	-47.91M	249.43M	-104.15M	-228.09M	-256.42M	150.08M	-512.71M	-14.59M	-33.17M	321.81M	41.45M	13.58M	34.01M	171.74M	-383.52M	153.64M	-194.05M	357.40M
Tax Provisions (Quarter)	-0.14M	-0.35M	0.24M	0.09M	0.88M	3.39M	1.32M	7.94M	4.00M	9.36M	7.76M	-5.12M	5.33M	7.10M	0.40M	12.98M	63.99M	-43.30M	-14.10M	4.58M
Profit After Tax (Quarter)	-167.25M	-81.41M	-48.14M	-121.98M	-105.03M	-231.48M	-257.74M	-109.24M	-516.75M	-23.94M	-40.94M	45.66M	36.12M	6.46M	33.61M	159.05M	-447.51M	196.89M	-50.57M	-412.23M
Income from Continuing Operations (Quarter)	-167.25M	-81.41M	-48.14M	249.33M	-105.03M	-231.48M	-257.74M	142.14M	-516.71M	-23.94M	-40.94M	326.93M	36.12M	6.48M	33.61M	158.76M	-447.51M	196.94M	-179.95M	352.82M
Consolidated Net Income (Quarter)	-167.25M	-81.41M	-48.14M	249.33M	-105.03M	-231.48M	-257.74M	142.14M	-516.71M	-23.94M	-40.94M	326.93M	36.12M	6.48M	33.61M	158.76M	-447.51M	196.94M	-179.95M	352.82M
Income towards Parent Company (Quarter)	-167.25M	-81.41M	-48.14M	249.33M	-105.03M	-231.48M	-257.74M	142.14M	-516.71M	-23.94M	-40.94M	326.93M	36.12M	6.48M	33.61M	158.76M	-447.51M	196.94M	-179.95M	352.82M
Net Income towards Common Stockholders (Quarter)	-167.25M	-81.41M	-48.14M	249.33M	-105.03M	-231.48M	-257.74M	142.14M	-516.75M	-23.94M	-40.94M	45.66M	36.55M	6.80M	34.02M	174.87M	-447.51M	201.19M	-179.95M	-282.85M
Additional items
EPS (Basic) (Quarter)	-2.10	-1.02	-0.60	-1.43	-1.20	-2.65	-2.94	-1.24	-5.86	-0.27	-0.46	0.76	0.38	0.07	0.35	1.65	-4.60	2.01	-0.50	-3.93
EPS (Weighted Average and Diluted) (Quarter)		-1.02	-0.60	-1.43		-2.65	-2.94	-1.24		-0.27	-0.46	0.76	0.37	0.07	0.34	1.50	-4.60	1.89	-0.50	-3.93
Shares Outstanding (Weighted Average) (Quarter)	0.08M	79.60M	0.08M	81.26M	87.25M	87.51M	87.47M	87.56M	88.19M	88.74M	88.89M	92.40M	93.99M	94.31M	94.67M	95.08M	97.36M	97.69M	98.55M	100.12M
Shares Outstanding (Diluted Average) (Quarter)										88.74M	88.61M	92.40M		99.14M	99.57M	107.88M		106.62M	98.55M	100.12M
EBITDA (Quarter)	-167.26M	-81.40M	-48.17M	-121.98M	-105.31M	-233.66M	-258.46M	-107.70M	-515.51M	-24.58M	-40.52M	47.21M	34.51M	6.12M	36.89M	161.68M	-300.39M	196.81M	-179.68M	-411.58M
Interest Expenses (Quarter)	15.65M	15.83M	20.65M	11.16M	17.27M	16.96M	6.32M	6.69M
Tax Rate (Quarter)	0.09%	0.43%	-0.49%	0.04%	-0.84%	-1.49%	-0.51%	5.29%	-0.78%	-64.14%	-23.40%	-1.59%	12.86%	52.29%	1.16%	7.56%	-16.69%	-28.18%	7.27%	1.28%

Research Tools

Sarepta Therapeutics Income Statement (2010-2025) | SRPT

Create an account

Sign In

Reset Password